MPL W515L mutation in Chinese patients with myeloproliferative diseases

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 955-958

  Xu, Wei ^a   Li, Jian Yong ^a   Xia, Jun ^a   Zhang, Su Jiang ^a   Fan, Lei ^a   Qiao, Chun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

JAK2V617F; MPLW515L; Mutation; Myeloproliferative disease

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2 V617F; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR W515L;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; CHINESE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC SCREENING; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; THROMBOCYTHEMIA;

ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 46749091270     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802035966     Document Type: Article

References (16)

1. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G. and Huntly, B. J. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, pp. 387-397.
2. James, C., Ugo, V., Le Couedic, J P, Staerk, J., Delhommeau, F. and Lacout, C. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, pp. 1144-1148.
3. Jones, A. V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C. and Zhang, L. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, pp. 2162-2168.
4. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N. and Swanton, S. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, pp. 1054-1061.
5. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R. and Passweg, J. R. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352, pp. 1779-1790.
6. Levine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S. and Chagnon, P. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood, 107, pp. 4139-4141.
7. Campbell, P. J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R. and Hasselbalch, H. C. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, pp. 2098-2100.
8. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q. and Krantz, S. B. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem, 280, pp. 22788-22792.
9. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y. and Zarnegar, S. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA, 102, pp. 18962-18967.
10. Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H. and Gilliland, D. G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 107, pp. 4274-4281.
11. Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A. and Wadleigh, M. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood, 108, pp. 3472-3476.
12. Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L. and Gozo, M. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med, 3, p. e270.
13. Vardiman, J. W., Brunning, R. D. and Harris, N. L. (2001) WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues, pp. 17-44. IARC Press, Lyon, France
14. Zhang, S. J., Li, J. Y., Li, W. D., Song, J. H., Xu, W. and Qiu, H. X. (2007) The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol, 29, pp. 71-72.
15. Lasho, T. L., Pardanani, A., McClure, R. F., Mesa, R. A., Levine, R. L. and Gilliland, D. G. (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: Chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol, 135, pp. 683-687.
16. Hu, W. Y., Zhao, Y., Ishii, T., Sozer, S., Shi, J. and Zhang, W. (2007) Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br J Haematol, 137, pp. 378-379.